Orphan medicinal products’ access to the Bulgarian pharmaceutical market – challenges and obstacles

References

• Drummond M. Challenges in the economic evaluation of orphan drugs. Eurohealth. 2008;14(2):16–17.
   Google Scholar
• Picavet E, Cassiman D, Simoens S. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses. J Clin Pharm Ther. 2015;40(3):304–307.
   PubMed Web of Science ®Google Scholar
• Nicod E, Kanavos P. Scientific and social value judgments for orphan drugs in health technology assessment. Int J Technol Assess Health Care. 2016;32(4):218–232.
   PubMed Web of Science ®Google Scholar
• European Federation of Pharmaceutical Industries and Associations. The pharmaceutical industry in figures. 2017. Available from: https://www.efpia.eu/media/219735/efpia-pharmafigures2017_statisticbroch_v04-final.pdf
   Google Scholar
• Lopert R. Pharmaceutical policy in Bulgaria. Pharmaceutical Policy in Countries with Developing Healthcare Systems. 2017. 151–168. Available from: https://link.springer.com/chapter/10.1007/978-3-319-51673-8_8
   Google Scholar
• Zlatareva A, Tachkov K, Stoicheva M, et al. Modelling the financial framework of the pharmacotherapy cost of rare diseases with orphan medicines—part II. Mod Economy. 2014;5(5):499–505. Available from: http://file.scirp.org/Html/4-7200770_46067.htm
   Google Scholar
• Official website of Bulgarian Drug Agency (BDA). Available from: http://www.bda.bg/en/legal-acts
   Google Scholar
• Regulation on the terms, rules and procedure for regulation and registration of prices for medicinal products in Bulgaria/2013. Official website of National Council of Pricing and Reimbursement in Bulgaria. Available from: http://www.ncpr.bg/en/
   Google Scholar
• Official website of NHIF. Available from: www.nhif.bg
   Google Scholar
• Regulation No. 9 of 01.12.2015 on the conditions and procedures for conducting HTA in Bulgaria. Official website of National Center of Public Health and Analyses in Bulgaria. Available from: http://ncpha.government.bg/index.php?option=com_content&view=category&layout=blog&id=373&Itemid=660&lang=en
   Google Scholar
• Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011;71(4):488–496.
   PubMed Web of Science ®Google Scholar
• Gammie T, Lu C, Ud-Din Babar Z. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. Plos One. 2015;10(10):e0140002.
   PubMed Web of Science ®Google Scholar
• Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011;6:62.
   PubMed Web of Science ®Google Scholar
• Young KE, Soussi I, Toumi M. The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change. J Mark Access Health Policy. 2017;1369817(5):1–11.
   Google Scholar
• Rawson NS. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost. Orphanet J Rare Dis. 2017;12(1):59.
   PubMedGoogle Scholar
• Morel T, Arickx F, Befrits G, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis. 2013;8:198.
   PubMed Web of Science ®Google Scholar
• London: National Institute for Health and Care Excellence (NICE). Citizens Council Reports No. 4. NICE Citizens Council Reports. 2004 Nov.
   Google Scholar
• Tadros N, McCormick J Towards a new way of evaluating orphan drugs at CADTH, White Paper. McKesson Canada. 2016. Available from: https://www.canadianinstitute.com/wp-content/uploads/2016/07/Orphan-Drugs-at-CADTH_McKesson.pdf
   Google Scholar
• Janoudi G, Amegatse W, McIntosh B, et al. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review. Orphanet J Rare Dis. 2016;11(1):164.
   PubMedGoogle Scholar
• Schuller Y, Hollak CE, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review. Orphanet J Rare Dis. 2015;10:92.
   PubMed Web of Science ®Google Scholar
• Adkins E, Nicholson L, Floyd D, et al. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category? Clinicoecon Outcomes Res. 2017;10(9):327–342.
   Google Scholar
• Kaczyńsk L, Serafin B, Przada-Machno P, et al. Is the cost-effectiveness threshold cost-effective in cancer therapy? Int J Health Econ Manag. 2015;2:69–78.
   Google Scholar
• Ollendorf D, Chapman R, Pearson S. Assessing the effectiveness and value of drugs for rare conditions a technical brief for the ICER orphan drug assessment & pricing summit. Inst Clin Econ Rev. May 2017. Available from: https://icer-review.org/wp-content/uploads/2017/02/ICER_Assessing-the-Value-of-Drugs-for-Rare-Conditions_051017.pdf
   Google Scholar
• Schurer M, Mason N, Chapman AM et al. Are orphan drugs treated equally across Europe? An HTA case study. ISPOR 21st Annual International Meeting; 2016 May 21–25; Washington, DC, USA.
   Google Scholar
• Carrera P, IJzerman M. Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):435–437.
   PubMed Web of Science ®Google Scholar
• Boon W, Martins L, Koopmanschap M. Governance of conditional reimbursement practices in The Netherlands. Health Policy. 2015;119(2):180–185.
   PubMed Web of Science ®Google Scholar
• Garau M, Mestre-Ferrandiz J. Access mechanisms for orphan drugs: a comparative study of selected European countries, OHE research briefing. Off Health Econ. 2009;52:1–32
   Google Scholar
• Lockhart C Value assessment of orphan drugs and treatments for rare diseases. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science. Univerity of Washington. 2016.
   Google Scholar
• Zelei T, Molnár MJ, Szegedi M, et al. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. Orphanet J Rare Dis. 2016;11(1):72.
   PubMed Web of Science ®Google Scholar
• Hakkaart L Novel developments in HTA methodology. International Conference on Rare Diseases & Orphan drugs (ICORD) 2014. Available from: http://icord.se/wp-content/uploads/2014/11/Session-III-Leona-Hakkaart.pdf
   Google Scholar
• Iskrov G, Stefanov R. Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. Orphan Drugs: Res Rev. 2014;4:1–9.
   Google Scholar
• Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014;15:335–340.
   PubMed Web of Science ®Google Scholar
• Reports about the pharmaceutical expenditures in Bulgaria. Official website of National Health Insurance Fund in Bulgaria. Available from: https://www.nhif.bg/page/218
   Google Scholar
• Dimitrova M, Petrova G, Kamusheva, et al. Budget and patient access analysis to second line therapy of multiple sclerosis in Bulgaria. ISPOR 19th Annual European Congress Vienna; 2016; Austria.
   Google Scholar
• Costs paid by NHIF and Ministry of Health for 2014–2016. Officially published in the website of Ministry of Health. Available from: http://www.mh.government.bg/media/filer_public/2015/06/16/may-19-actuarial-model-sheet-3-razhoden-modul-bg.pdf
   Google Scholar
• Zlatareva А, Tachkov K, Stoicheva M, et al. Financial analysis of the access to pharmacotherapy for rare diseases in Bulgaria. Mod Economy. 2014;5:461–467.
   Google Scholar
• Kamusheva M, Stoimenova A, Doneva M, et al. A cross-country comparison of reimbursed orphan medicines in Bulgaria, Greece and Romania. Biotechnol Biotechnol. Eq. 2013:27(5);4186–4191.
   Web of Science ®Google Scholar
• National program for prevention of chronic non-communicable diseases in Bulgaria 2014–2020. Adopted in 2013 by the Council of Ministers of the Republic of Bulgaria. Available from: http://ncphp.government.bg
   Google Scholar
• Hughes-Wilson W, Palma A, Schuurman A, et al. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.
   PubMed Web of Science ®Google Scholar
• Logviss K, Krievins D, Purvina S. Impact of orphan drugs on Latvian budget. Orphanet J Rare Dis. 2016;11(1):59.
   PubMedGoogle Scholar
• Schlander M, Garattini S, Holm S, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res. 2014;3(4):399–422.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? Orphanet J Rare Dis. 2017;12(1):1.
   PubMedGoogle Scholar
• Schlander M, Garattini S, Kolominsky-Rabas P, et al. Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. J Mark Access Health Policy. 2016;4:33039.
   Google Scholar